This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
OTC
VILOXAZINE HYDROCHLORIDE
EQ 200MG BASE, Capsule, extended release
INN: VILOXAZINE HYDROCHLORIDE
Data updated: 2026-04-25
Available in:
🇬🇧🇵🇹
Form
CAPSULE, EXTENDED RELEASE
Dosage
EQ 200MG BASE
Route
ORAL
Storage
—
About This Product
Manufacturer
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
SUPERNUS PHARMACEUTICALS INC
ATC Code
N06AX09
Source
FDA_OB · 211964
USDailyMed:Viloxazine
N06AX09(WHO)
US:℞-only
(RS)-2-[(2-ethoxyphenoxy)methyl]morpholine
46817-91-8NHCl:35604-67-2Y
5666
DB09185YHCl:DBSALT001262
5464YHCl:64514
5I5Y2789ZFHCl:OQW30I1332Y
D08673YHCl:D02572
CHEBI:94405
ChEMBL306700YHCl:ChEMBL2106483
DTXSID6057900
Interactive imageHCl:Interactive image
CCOC1=CC=CC=C1OCC1CNCCO1HCl: Cl.CCOC1=CC=CC=C1OCC1CNCCO1
InChI=1S/C13H19NO3/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11/h3-6,11,14H,2,7-10H2,1H3YKey:YWPHCCPCQOJSGZ-UHFFFAOYSA-NYHCl: InChI=1S/C13H19NO3.ClH/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11;/h3-6,11,14H,2,7-10H2,1H3;1HKey:HJOCKFVCMLCPTP-UHFFFAOYSA-N
Viloxazine, sold under the brand nameQelbreeamong others, is aselective norepinephrine reuptake inhibitormedication that is indicated in the treatment ofattention deficit hyperactivity disorder(ADHD) in children and adults.It was marketed for almost 30years as anantidepressantfor the treatment ofdepressionbefore being discontinued and subsequently repurposed as a treatment for ADHD.Viloxazine is takenorally.It was used as an antidepressant in animmediate-releaseform and is used in ADHD in anextended-releaseform,although current evidence indicates that it is significantly less effective at reducing ADHD symptoms compared to stimulant medications likemethylphenidate.
Side effectsof viloxazine includeinsomnia,headache,somnolence,fatigue,nausea,vomiting,decreased appetite,dry mouth,constipation,irritability,increased heart rate, andincreased blood pressure.Rarely, the medication may causesuicidal thoughtsandbehaviors.It can also activatemaniaorhypomaniain people withbipolar disorder.Viloxazine acts as aselectivenorepinephrine reuptake inhibitor(sNRI).The immediate-release form has anelimination half-lifeof 2.5hourswhile the half-life of the extended-release form is 7hours.
Viloxazine was first described by 1972and was marketed as an antidepressant in Europe in 1974.It was not marketed in the United States at this time.The medication was discontinued in 2002 for commercial reasons.However, it was repurposed for the treatment of ADHD and was reintroduced, in the United States, in April 2021.Viloxazine is anon-stimulantmedication; it has no knownmisuse liabilityand is not acontrolled substance.
